<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sredob</journal-id><journal-title-group><journal-title xml:lang="ru">Здоровье населения и среда обитания – ЗНиСО</journal-title><trans-title-group xml:lang="en"><trans-title>Public Health and Life Environment – PH&amp;LE</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-5238</issn><issn pub-type="epub">2619-0788</issn><publisher><publisher-name>ФБУЗ ФЦГиЭ Роспотребнадзора</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35627/2219-5238/2025-33-4-7-18</article-id><article-id custom-type="elpub" pub-id-type="custom">sredob-2461</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВОПРОСЫ УПРАВЛЕНИЯ И СОЦИАЛЬНОЙ ГИГИЕНЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ISSUES OF MANAGEMENT AND SOCIAL HYGIENE</subject></subj-group></article-categories><title-group><article-title>Оптимизация расходов при оказании медицинской помощи онкологическим больным: систематический обзор международных публикаций</article-title><trans-title-group xml:lang="en"><trans-title>Optimization of Cancer Care Costs: A Systematic Review of International Publications</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2921-3272</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куделина</surname><given-names>Ольга Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Kudelina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, доцент, профессор кафедры организации здравоохранения и общественного здоровья, ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России</p></bio><bio xml:lang="en"><p>Olga V. Kudelina, Dr. Sci. (Med.), docent; Professor, Department of Healthcare Organization and Public Health</p></bio><email xlink:type="simple">koudelina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7947-360X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гамирова</surname><given-names>Кристина Анатольевна</given-names></name><name name-style="western" xml:lang="en"><surname>Gamirova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аспирант кафедры организации здравоохранения и общественного здоровья</p></bio><bio xml:lang="en"><p>Kristina A. Gamirova, Postgraduate Student, Department of Healthcare Organization and Public Health</p></bio><email xlink:type="simple">cristine@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9029-4326</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шерьязданова</surname><given-names>Динара Нурланова</given-names></name><name name-style="western" xml:lang="en"><surname>Sheryazdanova</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>PhD, ассоциированный профессор кафедры внутренних болезней</p></bio><bio xml:lang="en"><p>Dinara N. Sheryazdanova, PhD, Assoc. Prof., Department of Internal Medicine</p></bio><email xlink:type="simple">sheryazdanova.dinara@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет, г. Томск</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>«Сибирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Карагандинский медицинский университет</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Karaganda Medical University</institution><country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>05</month><year>2025</year></pub-date><volume>33</volume><issue>4</issue><fpage>7</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Куделина О.В., Гамирова К.А., Шерьязданова Д.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Куделина О.В., Гамирова К.А., Шерьязданова Д.Н.</copyright-holder><copyright-holder xml:lang="en">Kudelina O.V., Gamirova K.A., Sheryazdanova D.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://zniso.fcgie.ru/jour/article/view/2461">https://zniso.fcgie.ru/jour/article/view/2461</self-uri><abstract><sec><title>Введение</title><p>Введение. Злокачественные новообразования представляют собой серьезную проблему не только из-за растущего уровня заболеваемости и высокой смертности, но и ввиду значительных финансовых затрат, как прямых (на диагностику и лечение), так и косвенных (потеря трудоспособности, инвалидизация, утраченные годы жизни и др.) Исследования, рассматривающие вопросы финансовых аспектов оказания онкологической помощи, направлены на изучение уже существующих подходов к вопросам финансирования, выявление новых тенденций и прогнозирование будущих направлений в этой области.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: сформировать направления оптимизации финансирования медицинской помощи онкологическим пациентам на основе анализа международных исследований, опубликованных в 2014-2024 гг.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Поисковый запрос публикаций в международной базе данных Web of Science проведен по дескрипторам: «oncology», «cancer», «healthcare», «medical care», «health care», «health system». Анализ 173 отобранных научных работ выполнен с помощью программы «Bibliometrix 3.0». В систематический обзор вошли материалы 39 наиболее релевантных статей, содержащих информацию о расходах на предоставление медицинской помощи онкологическим больным и способам их оптимизации.</p></sec><sec><title>Результаты</title><p>Результаты. В большинстве стран мира расходы на лечение онкологических заболеваний составляют существенную часть от общего объема средств, выделяемых на здравоохранение. Исследователи предлагают различные подходы к снижению издержек на оказание помощи онкологическим пациентам. Выделены три ключевых направления международных публикаций, рассматривающих способы эффективного использования средств при оказании медицинской помощи: оценка затрат на лечение рака; изучение факторов, влияющих на стоимость лечения онкологических заболеваний, и оценка способов снижения стоимости терапии злокачественных новообразований.</p></sec><sec><title>Выводы</title><p>Выводы. Определены основные стратегии и методы рационального использования финансовых средств в онкологии. Эти подходы могут быть адаптированы под конкретные условия и потребности различных лечебных учреждений, оказывающих медицинскую помощь онкологическим пациентам. Их реализация требует совместных усилий правительства, учреждений здравоохранения, профессиональных ассоциаций и общества в целом.</p></sec></abstract><trans-abstract xml:lang="en"><p>Introduction: Malignant neoplasms pose a serious challenge due to significant economic costs, both direct (diagnosis and treatment) and indirect (sickness absence, disability, years of life lost, etc.). The studies addressing financial aspects of cancer care are aimed at examining already existing approaches to funding, identifying new trends, and forecasting future directions.Objective: To formulate directions for optimizing cancer care costs based on the analysis of international studies published between 2014 and 2024.Materials and methods: Publications were selected from the Web of Science international database using the following search queries: “oncology”, “cancer”, “healthcare”, “medical care”, “health care”, and “health system”. Metadata from 173 selected papers were then analyzed using the Bibliometrix 3.0 software. The systematic review included materials of 39 most relevant publications containing information about cancer care costs and ways of their optimization.Results: In most countries, costs of cancer treatment constitute a significant proportion of the total funds allocated for healthcare. Researchers propose various approaches to reducing these expenses. We identified three key directions of international publications examining ways to use cancer care resources effectively: assessment of cancer treatment costs, investigation of factors influencing them, and evaluation of cancer care cost reduction opportunities.Conclusions: We defined the main strategies and methods for rational use of financial resources in oncology. These approaches can be adapted to specific conditions and needs of various health facilities providing cancer care. Their implementation requires joint efforts by the government, medical institutions, professional associations, and the society as a whole.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>онкологическая помощь</kwd><kwd>организация здравоохранения</kwd><kwd>лечение</kwd><kwd>оптимизация</kwd><kwd>расходы на оказание медицинской помощи</kwd><kwd>систематический обзор</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cancer care</kwd><kwd>healthcare organization</kwd><kwd>treatment</kwd><kwd>optimization</kwd><kwd>healthcare cost</kwd><kwd>systematic review</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.А., Полякова К.И., Завьялов А.А. и др. Основные направления анализа экономических затрат при оказании онкологической помощи населению // ФАРМАКОЭКОНОМИКА. Современная Фармакоэкономика и Фармакоэпидемиология. 2019; 12 (4): 310-317. http://dx.doi.org/10.17749/2070-4909.2019.12.4.310-317</mixed-citation><mixed-citation xml:lang="en">Andreev DA, Polyakova KI, Zavyalov AA et al. Crucial areas of the economic analysis of public cancer care. FARMAKOEKONOMIKA Modern Pharmacoeconomic and Pharmacoepidemiology. 2020 Feb 18;12(4):310–7. (In Russ). http://dx.doi.org/10.17749/2070-4909.2019.12.4.310-317</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Banegas MP, Hassett MJ, Keast EM et al. Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer. Value in Health 2022 Jan;25(1):69–76. http://dx.doi.org/10.1016/j.jval.2021.06.016</mixed-citation><mixed-citation xml:lang="en">Banegas MP, Hassett MJ, Keast EM et al. Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer. Value in Health 2022 Jan;25(1):69–76. http://dx.doi.org/10.1016/j.jval.2021.06.016</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Espinoza MA, Armijo N, Abbott T, Jiménez J, Balmaceda C. El costo esperado de cáncer en Chile. Revista médica de Chile. 2022 Nov;150(11):1438–49 http://dx.doi.org/10.4067/s0034-98872022001101438</mixed-citation><mixed-citation xml:lang="en">Espinoza MA, Armijo N, Abbott T, Jiménez J, Balmaceda C. El costo esperado de cáncer en Chile. Revista médica de Chile. 2022 Nov;150(11):1438–49 http://dx.doi.org/10.4067/s0034-98872022001101438</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang I, Shin DW, Kang KH, Yang HK, Kim SY, Park JH. Medical Costs and Healthcare Utilization among Cancer Decedents in the Last Year of Life in 2009. Cancer Research and Treatment. 2016 Jan 15;48(1):365–75. http://dx.doi.org/10.4143/crt.2014.088</mixed-citation><mixed-citation xml:lang="en">Hwang I, Shin DW, Kang KH, Yang HK, Kim SY, Park JH. Medical Costs and Healthcare Utilization among Cancer Decedents in the Last Year of Life in 2009. Cancer Research and Treatment. 2016 Jan 15;48(1):365–75. http://dx.doi.org/10.4143/crt.2014.088</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Достижение благополучия: глобальная программа по обеспечению учета вопросов благополучия в общественном здравоохранении на основе концепции укрепления здоровья населения. Женева: Всемирная организация здравоохранения; 2024 r. Лицензия: CC BY-NC-SA 3.0 IGO</mixed-citation><mixed-citation xml:lang="en">Achieving well-being: a global framework for integrating well-being into public health utilizing a health promotion approach. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.А., Завьялов А.А., Ермолаева Т.Н. Методология оценки затрат системы здравоохранения на оказание онкологической помощи // Здравоохранение Российской Федерации. 2021; 65(2): 125-134. https://doi.org/10.47470/0044-197X-2021-65-2-125-134</mixed-citation><mixed-citation xml:lang="en">Andreev DA, Zavyalov AA, Ermolaeva TN. Methodological outlines for assessing the costs of cancer patients care. Health Care of the Russian Federation. 2021 May 11;65(2):125–34. (In Russ) http://dx.doi.org/10.47470/0044-197x-2021-65-2-125-134</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Куделина О. В., Канева М. А. Капитал здоровья и эффектность региональных систем здравоохранения: соответствия и противоречия. Проблемы социальной гигиены, здравоохранения и истории медицины. 2022;30(1):24—32. http://dx.doi.org/10.32687/0869-866X-2022-30-1-24-32</mixed-citation><mixed-citation xml:lang="en">Kudelina OV, Kaneva МA. The health capital and efficiency of regional health care systems: The conformances and contradictions. Problems of Social Hygiene Public Health and History of Medicine. 2022 Jan;30(1). (In Russ.) http://dx.doi.org/10.32687/0869-866x-2022-30-1-24-32</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Passas I. Bibliometric Analysis: The Main Steps. Encyclopedia. 2024 Jun 20;4(2):1014–25. http://dx.doi.org/10.3390/encyclopedia4020065</mixed-citation><mixed-citation xml:lang="en">Passas I. Bibliometric Analysis: The Main Steps. Encyclopedia. 2024 Jun 20;4(2):1014–25. http://dx.doi.org/10.3390/encyclopedia4020065</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Almobarak F. Bibliometric analysis of global research in palliative care for cervical cancer. Frontiers in Oncology. 2024 Aug 26;14. http://dx.doi.org/10.3389/fonc.2024.1432805</mixed-citation><mixed-citation xml:lang="en">Almobarak F. Bibliometric analysis of global research in palliative care for cervical cancer. Frontiers in Oncology. 2024 Aug 26;14. http://dx.doi.org/10.3389/fonc.2024.1432805</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Manoj Kumar L., George RJ, P.S. A. Bibliometric Analysis for Medical Research. Indian Journal of Psychological Medicine. 2022 Jul 11;45(3):277–82. http://dx.doi.org/10.1177/02537176221103617</mixed-citation><mixed-citation xml:lang="en">Manoj Kumar L., George RJ, P.S. A. Bibliometric Analysis for Medical Research. Indian Journal of Psychological Medicine. 2022 Jul 11;45(3):277–82. http://dx.doi.org/10.1177/02537176221103617</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chapel JM, Ritchey MD, Zhang D, Wang G. Prevalence and Medical Costs of Chronic Diseases Among Adult Medicaid Beneficiaries. American Journal of Preventive Medicine. 2017 Dec; 53(6):S143–54. http://dx.doi.org/10.1016/j.amepre.2017.07.019</mixed-citation><mixed-citation xml:lang="en">Chapel JM, Ritchey MD, Zhang D, Wang G. Prevalence and Medical Costs of Chronic Diseases Among Adult Medicaid Beneficiaries. American Journal of Preventive Medicine. 2017 Dec; 53(6):S143–54. http://dx.doi.org/10.1016/j.amepre.2017.07.019</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kokol P, Blažun Vošner H, Završnik J. Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Information &amp; Libraries Journal. 2020 Jan 29;38(2):125–38. http://dx.doi.org/10.1111/hir.12295</mixed-citation><mixed-citation xml:lang="en">Kokol P, Blažun Vošner H, Završnik J. Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Information &amp; Libraries Journal. 2020 Jan 29;38(2):125–38. http://dx.doi.org/10.1111/hir.12295</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Aria M, Cuccurullo C. bibliometrix : An R-tool for comprehensive science mapping analysis. Journal of Informetrics. 2017 Nov;11(4):959–75. http://dx.doi.org/10.1016/j.joi.2017.08.007</mixed-citation><mixed-citation xml:lang="en">Aria M, Cuccurullo C. bibliometrix : An R-tool for comprehensive science mapping analysis. Journal of Informetrics. 2017 Nov;11(4):959–75. http://dx.doi.org/10.1016/j.joi.2017.08.007</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lu W, Liu Z, Huang Y, Bu Y, Li X, Cheng Q. How do authors select keywords? A preliminary study of author keyword selection behavior. Journal of Informetrics. 2020 Nov;14(4):101066. http://dx.doi.org/10.1016/j.joi.2020.101066</mixed-citation><mixed-citation xml:lang="en">Lu W, Liu Z, Huang Y, Bu Y, Li X, Cheng Q. How do authors select keywords? A preliminary study of author keyword selection behavior. Journal of Informetrics. 2020 Nov;14(4):101066. http://dx.doi.org/10.1016/j.joi.2020.101066</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Huang L, Chen X, Ni X, Liu J, Cao X, Wang C. Tracking the dynamics of co-word networks for emerging topic identification. Technological Forecasting and Social Change. 2021 Sep;170:120944. http://dx.doi.org/10.1016/j.techfore.2021.120944</mixed-citation><mixed-citation xml:lang="en">Huang L, Chen X, Ni X, Liu J, Cao X, Wang C. Tracking the dynamics of co-word networks for emerging topic identification. Technological Forecasting and Social Change. 2021 Sep;170:120944. http://dx.doi.org/10.1016/j.techfore.2021.120944</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Yu Q, Zheng F, Long C, Lu Z, Duan Z. Comparing keywords plus of WOS and author keywords: A case study of patient adherence research. Journal of the Association for Information Science and Technology. 2015 Jan 8;67(4):967–72. http://dx.doi.org/10.1002/asi.23437</mixed-citation><mixed-citation xml:lang="en">Zhang J, Yu Q, Zheng F, Long C, Lu Z, Duan Z. Comparing keywords plus of WOS and author keywords: A case study of patient adherence research. Journal of the Association for Information Science and Technology. 2015 Jan 8;67(4):967–72. http://dx.doi.org/10.1002/asi.23437</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Xu H, Wang L, Xu D. Global publication productivity and research trends on recurrent ovarian cancer: a bibliometric study. Frontiers in Oncology. 2024 Jul 5;14. http://dx.doi.org/10.3389/fonc.2024.1422213</mixed-citation><mixed-citation xml:lang="en">Xu H, Wang L, Xu D. Global publication productivity and research trends on recurrent ovarian cancer: a bibliometric study. Frontiers in Oncology. 2024 Jul 5;14. http://dx.doi.org/10.3389/fonc.2024.1422213</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wang T, Li Y, Zheng X. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review. BMC Health Services Research. 2023 Jun 26;23(1). http://dx.doi.org/10.1186/s12913-023-09727-7</mixed-citation><mixed-citation xml:lang="en">Wang T, Li Y, Zheng X. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review. BMC Health Services Research. 2023 Jun 26;23(1). http://dx.doi.org/10.1186/s12913-023-09727-7</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Altini M, Solinas L, Bucchi L, et al. Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways. International Journal of Environmental Research and Public Health. 2020 Jul 2;17(13):4765. http://dx.doi.org/10.3390/ijerph17134765</mixed-citation><mixed-citation xml:lang="en">Altini M, Solinas L, Bucchi L, et al. Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways. International Journal of Environmental Research and Public Health. 2020 Jul 2;17(13):4765. http://dx.doi.org/10.3390/ijerph17134765</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yin X, Xu Y, Man X. et al. Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China. Cancer Medicine. 2019 May 7;8(6):3250–60. http://dx.doi.org/10.1002/cam4.2184</mixed-citation><mixed-citation xml:lang="en">Yin X, Xu Y, Man X. et al. Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China. Cancer Medicine. 2019 May 7;8(6):3250–60. http://dx.doi.org/10.1002/cam4.2184</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gorasso V, Vandevijvere S, Van der Heyden J et al. The incremental healthcare cost associated with cancer in Belgium: A registry‐based data analysis. Cancer Medicine. 2024 Jan 24;13(3). http://dx.doi.org/10.1002/cam4.6659</mixed-citation><mixed-citation xml:lang="en">Gorasso V, Vandevijvere S, Van der Heyden J et al. The incremental healthcare cost associated with cancer in Belgium: A registry‐based data analysis. Cancer Medicine. 2024 Jan 24;13(3). http://dx.doi.org/10.1002/cam4.6659</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Watanabe T, Goto R, Yamamoto Y, Ichinose Y, Higashi T. First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan. International Journal of Environmental Research and Public Health. 2021 Sep 7;18(18):9447. http://dx.doi.org/10.3390/ijerph18189447</mixed-citation><mixed-citation xml:lang="en">Watanabe T, Goto R, Yamamoto Y, Ichinose Y, Higashi T. First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan. International Journal of Environmental Research and Public Health. 2021 Sep 7;18(18):9447. http://dx.doi.org/10.3390/ijerph18189447</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wu SW, Pan Q, Chen T. Research on diagnosis-related group grouping of inpatient medical expenditure in colorectal cancer patients based on a decision tree model. World Journal of Clinical Cases. 2020 Jun 26;8(12):2484–93. http://dx.doi.org/10.12998/wjcc.v8.i12.2484</mixed-citation><mixed-citation xml:lang="en">Wu SW, Pan Q, Chen T. Research on diagnosis-related group grouping of inpatient medical expenditure in colorectal cancer patients based on a decision tree model. World Journal of Clinical Cases. 2020 Jun 26;8(12):2484–93. http://dx.doi.org/10.12998/wjcc.v8.i12.2484</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Haiderali A, Rhodes WC, Gautam S et al. Healthcare Resource Utilization and Cost Among Patients Treated for Early-Stage Triple-Negative Breast Cancer. Future Oncology. 2021 Jul 13;17(29):3833–41. http://dx.doi.org/10.2217/fon-2021-0531</mixed-citation><mixed-citation xml:lang="en">Haiderali A, Rhodes WC, Gautam S et al. Healthcare Resource Utilization and Cost Among Patients Treated for Early-Stage Triple-Negative Breast Cancer. Future Oncology. 2021 Jul 13;17(29):3833–41. http://dx.doi.org/10.2217/fon-2021-0531</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sieluk J, Haiderali A, Huang M, Yang L, Hirshfield KM. Early Triple-Negative Breast Cancer in Women Aged ≥65: Retrospective Study of Outcomes, Resource Use and Costs, 2010–2016. Future Oncology. 2020 Dec 2;17(9):1039–54. http://dx.doi.org/10.2217/fon-2020-0996</mixed-citation><mixed-citation xml:lang="en">Sieluk J, Haiderali A, Huang M, Yang L, Hirshfield KM. Early Triple-Negative Breast Cancer in Women Aged ≥65: Retrospective Study of Outcomes, Resource Use and Costs, 2010–2016. Future Oncology. 2020 Dec 2;17(9):1039–54. http://dx.doi.org/10.2217/fon-2020-0996</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Massa I, Balzi W, Burattini C et al. The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study). The Breast. 2017 Aug;34:103–7. http://dx.doi.org/10.1016/j.breast.2017.05.007</mixed-citation><mixed-citation xml:lang="en">Massa I, Balzi W, Burattini C et al. The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study). The Breast. 2017 Aug;34:103–7. http://dx.doi.org/10.1016/j.breast.2017.05.007</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wu CF, Xu L, Fu S, Peng HL, Messick CA, Lairson DR. Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. Journal of Managed Care &amp; Specialty Pharmacy. 2018 Nov;24(11):1156–64. http://dx.doi.org/10.18553/jmcp.2018.24.11.1156</mixed-citation><mixed-citation xml:lang="en">Wu CF, Xu L, Fu S, Peng HL, Messick CA, Lairson DR. Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. Journal of Managed Care &amp; Specialty Pharmacy. 2018 Nov;24(11):1156–64. http://dx.doi.org/10.18553/jmcp.2018.24.11.1156</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Hall PS, Hamilton P, Hulme CT et al. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. British Journal of Cancer. 2015 Jan 20;112(5):948–56. http://dx.doi.org/10.1038/bjc.2014.644</mixed-citation><mixed-citation xml:lang="en">Hall PS, Hamilton P, Hulme CT et al. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. British Journal of Cancer. 2015 Jan 20;112(5):948–56. http://dx.doi.org/10.1038/bjc.2014.644</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Park C, Park SK, Upshaw JN, Schonberg MA. In-hospital mortality, length of stay and hospital costs for hospitalized breast cancer patients with comorbid heart failure in the USA. Current Medical Research and Opinion. 2021 Sep 29;37(12):2043–7. http://dx.doi.org/10.1080/03007995.2021.1980775</mixed-citation><mixed-citation xml:lang="en">Park C, Park SK, Upshaw JN, Schonberg MA. In-hospital mortality, length of stay and hospital costs for hospitalized breast cancer patients with comorbid heart failure in the USA. Current Medical Research and Opinion. 2021 Sep 29;37(12):2043–7. http://dx.doi.org/10.1080/03007995.2021.1980775</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Sun SX, Leung AN, Dillon PW, Hollenbeak CS. Length of Stay and Readmissions in Mastectomy Patients. The Breast Journal. 2015 Jun 23;21(5):526–32 http://dx.doi.org/10.1111/tbj.12442</mixed-citation><mixed-citation xml:lang="en">Sun SX, Leung AN, Dillon PW, Hollenbeak CS. Length of Stay and Readmissions in Mastectomy Patients. The Breast Journal. 2015 Jun 23;21(5):526–32 http://dx.doi.org/10.1111/tbj.12442</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. Value in Health. 2015 Dec;18(8):1070–8. http://dx.doi.org/10.1016/j.jval.2015.08.008</mixed-citation><mixed-citation xml:lang="en">Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. Value in Health. 2015 Dec;18(8):1070–8. http://dx.doi.org/10.1016/j.jval.2015.08.008</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z, Leng J, Gao G, Zhang L, Yang Y. Direct inpatient costs and influencing factors for patients with rectal cancer with low anterior resection: a retrospective observational study at a three-tertiary hospital in Beijing, China. BMJ Open. 2018 Dec;8(12):e023116. http://dx.doi.org/10.1136/bmjopen-2018-023116</mixed-citation><mixed-citation xml:lang="en">Chen Z, Leng J, Gao G, Zhang L, Yang Y. Direct inpatient costs and influencing factors for patients with rectal cancer with low anterior resection: a retrospective observational study at a three-tertiary hospital in Beijing, China. BMJ Open. 2018 Dec;8(12):e023116. http://dx.doi.org/10.1136/bmjopen-2018-023116</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Löfgren A, Åkesson O, Johansson J, Persson J. Hospital costs and health-related quality of life from complications after esophagectomy. European Journal of Surgical Oncology. 2021 May;47(5):1042–7. http://dx.doi.org/10.1016/j.ejso.2020.09.032</mixed-citation><mixed-citation xml:lang="en">Löfgren A, Åkesson O, Johansson J, Persson J. Hospital costs and health-related quality of life from complications after esophagectomy. European Journal of Surgical Oncology. 2021 May;47(5):1042–7. http://dx.doi.org/10.1016/j.ejso.2020.09.032</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Qian MF, Betancourt NJ, Pineda A et al. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. The Oncologist. 2022 Oct 27;28(3):268–75. http://dx.doi.org/10.1093/oncolo/oyac219</mixed-citation><mixed-citation xml:lang="en">Qian MF, Betancourt NJ, Pineda A et al. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. The Oncologist. 2022 Oct 27;28(3):268–75. http://dx.doi.org/10.1093/oncolo/oyac219</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Arrieta O, Quintana-Carrillo R, Ahumada-Curiel G et al. Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico. Tobacco Induced Diseases. 2015;12(1):25. http://dx.doi.org/10.1186/s12971-014-0025-4</mixed-citation><mixed-citation xml:lang="en">Arrieta O, Quintana-Carrillo R, Ahumada-Curiel G et al. Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico. Tobacco Induced Diseases. 2015;12(1):25. http://dx.doi.org/10.1186/s12971-014-0025-4</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pendrith C, Thind A, Zaric GS, Sarma S. Costs of Cervical Cancer Treatment: Population-Based Estimates from Ontario. Current Oncology. 2016 Apr 1;23(2):109–15. http://dx.doi.org/10.3747/co.23.2598</mixed-citation><mixed-citation xml:lang="en">Pendrith C, Thind A, Zaric GS, Sarma S. Costs of Cervical Cancer Treatment: Population-Based Estimates from Ontario. Current Oncology. 2016 Apr 1;23(2):109–15. http://dx.doi.org/10.3747/co.23.2598</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Sargazi N, Daroudi R, Zendehdel K. et al. Economic Burden of Gynecological Cancers in Iran. Value in Health Regional Issue. 2022 Mar;28:1–6. http://dx.doi.org/10.1016/j.vhri.2021.02.005</mixed-citation><mixed-citation xml:lang="en">Sargazi N, Daroudi R, Zendehdel K. et al. Economic Burden of Gynecological Cancers in Iran. Value in Health Regional Issue. 2022 Mar;28:1–6. http://dx.doi.org/10.1016/j.vhri.2021.02.005</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Chen HM, Chen JH, Chiang SC, Lin YC, Ko Y. An evaluation of the healthcare costs of metastatic breast cancer. Medicine. 2021 Oct 29;100(43):e27567. http://dx.doi.org/10.1097/md.0000000000027567</mixed-citation><mixed-citation xml:lang="en">Chen HM, Chen JH, Chiang SC, Lin YC, Ko Y. An evaluation of the healthcare costs of metastatic breast cancer. Medicine. 2021 Oct 29;100(43):e27567. http://dx.doi.org/10.1097/md.0000000000027567</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Pimiento JM, Evans DC, Tyler et al. Value of nutrition support therapy in patients with gastrointestinal malignancies: a narrative review and health economic analysis of impact on clinical outcomes in the United States. Journal of Gastrointestinal Oncology. 2021 Apr;12(2):864–73. http://dx.doi.org/10.21037/jgo-20-326</mixed-citation><mixed-citation xml:lang="en">Pimiento JM, Evans DC, Tyler et al. Value of nutrition support therapy in patients with gastrointestinal malignancies: a narrative review and health economic analysis of impact on clinical outcomes in the United States. Journal of Gastrointestinal Oncology. 2021 Apr;12(2):864–73. http://dx.doi.org/10.21037/jgo-20-326</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Hung MC, Ekwueme DU, White A et al. Estimating health benefits and cost-savings for achieving the Healthy People 2020 objective of reducing invasive colorectal cancer. Preventive Medicine. 2018 Jan;106:38–44. http://dx.doi.org/10.1016/j.ypmed.2017.09.022</mixed-citation><mixed-citation xml:lang="en">Hung MC, Ekwueme DU, White A et al. Estimating health benefits and cost-savings for achieving the Healthy People 2020 objective of reducing invasive colorectal cancer. Preventive Medicine. 2018 Jan;106:38–44. http://dx.doi.org/10.1016/j.ypmed.2017.09.022</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Hylin H, Thrane H, Pedersen K, Kristiansen IS, Burger EA. The healthcare costs of treating human papillomavirus-related cancers in Norway. BMC Cancer. 2019 May 7;19(1). http://dx.doi.org/10.1186/s12885-019-5596-2</mixed-citation><mixed-citation xml:lang="en">Hylin H, Thrane H, Pedersen K, Kristiansen IS, Burger EA. The healthcare costs of treating human papillomavirus-related cancers in Norway. BMC Cancer. 2019 May 7;19(1). http://dx.doi.org/10.1186/s12885-019-5596-2</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen MD, Siersma V, Rasmussen JF, Brodersen J. Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study. BMJ Open. 2020 Jan;10(1):e031768: http://dx.doi.org/10.1136/bmjopen-2019-031768</mixed-citation><mixed-citation xml:lang="en">Jensen MD, Siersma V, Rasmussen JF, Brodersen J. Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study. BMJ Open. 2020 Jan;10(1):e031768: http://dx.doi.org/10.1136/bmjopen-2019-031768</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Kypriotakis G, Kim S, Karam-Hage M et al. Examining the Association between Abstinence from Smoking and Healthcare Costs among Patients with Cancer. Cancer Prevention Research. 2023 Nov 8;17(5):217–25. http://dx.doi.org/10.1158/1940-6207.capr-23-0245</mixed-citation><mixed-citation xml:lang="en">Kypriotakis G, Kim S, Karam-Hage M et al. Examining the Association between Abstinence from Smoking and Healthcare Costs among Patients with Cancer. Cancer Prevention Research. 2023 Nov 8;17(5):217–25. http://dx.doi.org/10.1158/1940-6207.capr-23-0245</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Kristina SA, Endarti D, Wiedyaningsih C, Fahamsya A, Faizah N. Health Care Cost of Noncommunicable Diseases Related to Smoking in Indonesia, 2015. Asia Pacific Journal of Public Health. 2018 Jan;30(1):29–35. http://dx.doi.org/10.1177/1010539517751311</mixed-citation><mixed-citation xml:lang="en">Kristina SA, Endarti D, Wiedyaningsih C, Fahamsya A, Faizah N. Health Care Cost of Noncommunicable Diseases Related to Smoking in Indonesia, 2015. Asia Pacific Journal of Public Health. 2018 Jan;30(1):29–35. http://dx.doi.org/10.1177/1010539517751311</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Steer KJ, Sun Z, Sadowski DC et al. The impact on clinical outcomes and healthcare resources from discontinuing colonoscopy surveillance subsequent to low-risk adenoma removal: A simulation study using the OncoSim-Colorectal model. Journal of Medical Screening. 2023 Sep 20;31(2):78–84. http://dx.doi.org/10.1177/09691413231202877</mixed-citation><mixed-citation xml:lang="en">Steer KJ, Sun Z, Sadowski DC et al. The impact on clinical outcomes and healthcare resources from discontinuing colonoscopy surveillance subsequent to low-risk adenoma removal: A simulation study using the OncoSim-Colorectal model. Journal of Medical Screening. 2023 Sep 20;31(2):78–84. http://dx.doi.org/10.1177/09691413231202877</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Hess LM, Cui ZL, Li XI, Oton AB, Shortenhaus S, Watson IA. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States. Journal of Medical Economics. 2018 May 11;21(8):755–61. http://dx.doi.org/10.1080/13696998.2018.1467918</mixed-citation><mixed-citation xml:lang="en">Hess LM, Cui ZL, Li XI, Oton AB, Shortenhaus S, Watson IA. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States. Journal of Medical Economics. 2018 May 11;21(8):755–61. http://dx.doi.org/10.1080/13696998.2018.1467918</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Palladino S, Perrone V, Giacomini E et al. Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy. Expert Review of Pharmacoeconomics &amp; Outcomes Research. 2023 Jul 17;23(9):1041–8. http://dx.doi.org/10.1080/14737167.2023.2234637</mixed-citation><mixed-citation xml:lang="en">Palladino S, Perrone V, Giacomini E et al. Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy. Expert Review of Pharmacoeconomics &amp; Outcomes Research. 2023 Jul 17;23(9):1041–8. http://dx.doi.org/10.1080/14737167.2023.2234637</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Lin HM, Pan X, Hou P et al. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. Journal of Medical Economics. 2020 May 21;23(8):894–901. http://dx.doi.org/10.1080/13696998.2020.1762620</mixed-citation><mixed-citation xml:lang="en">Lin HM, Pan X, Hou P et al. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. Journal of Medical Economics. 2020 May 21;23(8):894–901. http://dx.doi.org/10.1080/13696998.2020.1762620</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Chen P, Liu Y, Wen Y, Zhou C. Non‐small cell lung cancer in China. Cancer Communications.2022 Sep 8;42(10):937–70. http://dx.doi.org/10.1002/cac2.12359</mixed-citation><mixed-citation xml:lang="en">Chen P, Liu Y, Wen Y, Zhou C. Non‐small cell lung cancer in China. Cancer Communications.2022 Sep 8;42(10):937–70. http://dx.doi.org/10.1002/cac2.12359</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Bui CN, O’Day K, Flanders S et al. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of Managed Care &amp; Specialty Pharmacy. 2016 Feb;22(2):163–70. http://dx.doi.org/10.18553/jmcp.2016.22.2.163</mixed-citation><mixed-citation xml:lang="en">Bui CN, O’Day K, Flanders S et al. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of Managed Care &amp; Specialty Pharmacy. 2016 Feb;22(2):163–70. http://dx.doi.org/10.18553/jmcp.2016.22.2.163</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Franchi M, Tritto R, Torroni L, Reno C, La Vecchia C, Corrao G. Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study. Cancers. 2020 Jun 25;12(6):1691. http://dx.doi.org/10.3390/cancers12061691</mixed-citation><mixed-citation xml:lang="en">Franchi M, Tritto R, Torroni L, Reno C, La Vecchia C, Corrao G. Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study. Cancers. 2020 Jun 25;12(6):1691. http://dx.doi.org/10.3390/cancers12061691</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Stenehjem D, Lubinga SJ, Wu A, Betts KA. Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors. Journal of Managed Care &amp; Specialty Pharmacy. 2023 Sep;29(9):1054–64. http://dx.doi.org/10.18553/jmcp.2023.29.9.1054</mixed-citation><mixed-citation xml:lang="en">Stenehjem D, Lubinga SJ, Wu A, Betts KA. Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors. Journal of Managed Care &amp; Specialty Pharmacy. 2023 Sep;29(9):1054–64. http://dx.doi.org/10.18553/jmcp.2023.29.9.1054</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Norum J, Grindedal EM, Heramb C et al. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. ESMO Open. 2018;3(3):e000328 http://dx.doi.org/10.1136/esmoopen-2018-000328</mixed-citation><mixed-citation xml:lang="en">Norum J, Grindedal EM, Heramb C et al. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. ESMO Open. 2018;3(3):e000328 http://dx.doi.org/10.1136/esmoopen-2018-000328</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Seung SJ, Mittmann N, Ante Z et al. Evaluating Real World Health System Resource Utilization and Costs for a Risk-Based Breast Cancer Screening Approach in the Canadian PERSPECTIVE Integration and Implementation Project. Cancers. 2024 Sep 18;16(18):3189. http://dx.doi.org/10.3390/cancers16183189</mixed-citation><mixed-citation xml:lang="en">Seung SJ, Mittmann N, Ante Z et al. Evaluating Real World Health System Resource Utilization and Costs for a Risk-Based Breast Cancer Screening Approach in the Canadian PERSPECTIVE Integration and Implementation Project. Cancers. 2024 Sep 18;16(18):3189. http://dx.doi.org/10.3390/cancers16183189</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Shih YCT, Xu Y, Bradley C, Giordano SH, Yao J, Yabroff KR. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. JNCI: Journal of the National Cancer Institute. 2022 Sep 13;114(10):1392–9. http://dx.doi.org/10.1093/jnci/djac141</mixed-citation><mixed-citation xml:lang="en">Shih YCT, Xu Y, Bradley C, Giordano SH, Yao J, Yabroff KR. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. JNCI: Journal of the National Cancer Institute. 2022 Sep 13;114(10):1392–9. http://dx.doi.org/10.1093/jnci/djac141</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
